News
Discover key insights from Supernus Pharmaceuticals' Q2 2025 earnings, including revenue growth, new product launches, the Sage Therapeutics ...
In December 2024, Blarcamesine (ANAVEX2-73) has been accepted for review by the EMA for the treatment of Alzheimer’s disease.
3d
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Detailed price information for Phathom Pharmaceuticals Inc (PHAT-Q) from The Globe and Mail including charting and trades.
Loved ones, caregivers and supporters of Wyomingites living with Alzheimer’s disease will join together Saturday, Aug. 23, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback